Adicet Bio (ACET) Prices 6.25M Share Offering at $14/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Adicet Bio (ACET) Announces Proposed Follow-On Offering of Common Stock
December 7, 2021 4:16 PM ESTAdicet Bio, Inc. (Adicet) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced that it has commenced an underwritten public offering of its common stock. Adicet also intends to grant the... More
Adicet Bio Inc. (ACET) PT Raised to $33 at Guggenheim
December 6, 2021 10:11 AM ESTGuggenheim analyst Michael Schmidt raised the price target on Adicet Bio Inc. (NASDAQ: ACET) to $33.00 (from $22.00) while maintaining a Buy rating.
... MorePre-Open Stock Movers 12/06: (TACO) (ACET) (VYNE) Higher; (LCID) (RIOT) (MARA) Lower (more...)
December 6, 2021 9:25 AM ESTPre-Open Stock Movers
Del Taco Restaurants, Inc. (NASDAQ: TACO) 64.7% HIGHER; Jack in the Box Inc. (NASDAQ: JACK), one of the nations leading QSR chains, and Del Taco Restaurants, Inc. (NASDAQ: TACO), the nations second largest Mexican QSR chain by number of restaurants, today announced that the companies have entered into a definitive agreement... More
Adicet Bio (ACET) Climbs 29% Following Positive Interim Clinical Data for Gamma Delta CAR T Investigational Cell Therapy
December 6, 2021 7:23 AM ESTAdicet Bio (NASDAQ: ACET) Climbs 29% Following Positive Interim Clinical Data for Gamma Delta CAR T Investigational Cell Therapy
... MoreAdicet Bio (ACET) Reports Positive Interim Clinical Data for Gamma Delta CAR T Investigational Cell Therapy
December 6, 2021 7:05 AM EST(Updated - December 6, 2021 7:23 AM EST, update corrects name in headline)
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced positive interim data from its dose escalation Phase 1 study evaluating the safety and tolerability of ADI-001, Adicets investigational therapy targeting CD20 for the potential treatment of B-cell Non-Hodgkins Lymphoma.
As of the November 22, 2021 data cutoff, six patients had been enrolled and received ADI-001. The first two patients enrolled in the lowest dose level... More
